Rigel Pharmaceuticals Inc - Company & Market Research Reports

Following a company allows Research and Markets to customize your experience and provide personalized recommendations.

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

From
From
Psoriatic Arthritis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriatic Arthritis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 241 Pages
From
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator
adroll